COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03EOF
|
|||
Drug Name |
Meplazumab
|
|||
Synonyms |
Mepolizumab
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 1/2 | [1] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN basigin (BSG) | Target Info | Inhibitor | [2] |
Meplazumab, a humanized anti-CD147 antibody, blocks the infection of SARS-CoV-2 since host-cell-expressed CD147 can bind to spike protein of SARS-CoV-2 and involve in host cell invasion. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04275245) Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia. U.S. National Institutes of Health. | |||
2 | Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.